1194MO Canakinumab
1194MO Canakinumab
Novartis top-line results for CANOPY-1 Phase III study support ...
Canakinumab is a potential first-in-class interleukin-1beta (IL-1β) inhibitor of the Pro-Tumor Inflammation (PTI) pathway in NSCLC6. PTI, which ...
Novartis provides update on Phase III study evaluating ...
Canakinumab development program continues; two Phase III non-small cell lung cancer clinical trials are ongoing in first-line and adjuvant ...